NICE scopes Sanofi/Regeneron's Zaltrap for colorectal cancer
This article was originally published in Scrip
Sanofi/Regenron's Zaltrap (aflibercept) will shortly be up for review by NICE, the health technology appraisal institute for England and Wales, as a treatment for metastatic colorectal cancer that has progressed after oxaliplatin-based chemotherapy. The institute has put out for consultation its draft scope.
You may also be interested in...
After arbitrators set an unpalatably low price for the company, bluebird is withdrawing its Zyntgelo gene therapy from Germany. The company also announced it would be restructuring its workforce, with job losses expected.
NICE will develop standards for using real world data as part of a new five-year strategic plan that the UK health technology assessment body hopes will make it a leader in the use of research and data.
International reference pricing is becoming more irrelevant as increasing emphasis is placed on other cost-containment measures.